Moolec ScienceMLEC +3.02%46 3-Year ROIIC % is 0.04 as of Jun. 2025, which is at its 10-year median of 0.04. GuruFocus rates MLEC with a GF Score™ of 46/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,325 Biotechnology companies, Moolec Science ranks better than 52.75% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Moolec Science's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 0.04%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Moolec Science's 3-Year ROIIC % or its related term are showing as below:
MLEC's 3-Year ROIIC % is ranked better than 52.75% of 1325
companies
in the Biotechnology industry
Industry Median: -4.44
vs MLEC: 0.04
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Moolec Science 3-Year ROIIC % Related Terms
Moolec Science 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Moolec Science's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs GNPX, ADIL, APVO: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Moolec Science's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Moolec Science's 3-Year ROIIC % falls into.
Moolec Science's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.51 (Jun. 2025) - -3.652 (Jun. 2022) )
/
( 402.247 (Jun. 2025) - 7.469 (Jun. 2022) )
=
0.142
/
394.778
=
0.04%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Moolec Science (MLEC) has a 3-Year ROIIC % of 0.04 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Moolec Science and its competitors. This is near median its historical median of 0.04. Over the past decade, Moolec Science's 3-Year ROIIC % has ranged from 0.04 to 0.04. According to the industry distribution chart, Moolec Science ranks #626 out of 1325 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Moolec Science's 3-Year ROIIC % too high?
Moolec Science's current 3-Year ROIIC % of 0.04 is near median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.04. Based on the distribution chart, Moolec Science ranks #626 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's 3-Year ROIIC % compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #626 out of 1325 companies for 3-Year ROIIC %. This puts Moolec Science in the upper half of its industry. Historically, Moolec Science's own 3-Year ROIIC % has ranged from 0.04 to 0.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Moolec Science and its competitors. Moolec Science's current 3-Year ROIIC % is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.97 — trading 90.6% below its estimated fair value. The current 3-Year ROIIC % is 0.04, which is near median its 10-year median of 0.04. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Moolec Science (MLEC), the current 3-Year ROIIC % is 0.04 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.97 is trading 90.6% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
3-Year ROIIC %: 0.04 (near median its 10-year median of 0.04)
GF Value™: $84.84 vs. price of $7.97 (90.6% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
